Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors

PURPOSE: Before anaplastic lymphoma kinase (ALK) inhibitors, treatment options for ALK-positive inflammatory myofibroblastic tumors (AP-IMTs) were unsatisfactory. We retrospectively analyzed the outcome of patients with AP-IMT treated with crizotinib to document response, toxicity, survival, and fea...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JCO Precis Oncol
Auteurs principaux: Trahair, Toby, Gifford, Andrew J., Fordham, Ashleigh, Mayoh, Chelsea, Fadia, Mitali, Lukeis, Robyn, Wood, Andrew C., Valvi, Santosh, Walker, Roderick D., Blackburn, James, Heyer, Erin E., Mercer, Tim R., Barbaric, Draga, Marshall, Glenn M., MacKenzie, Karen L.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2019
Sujets:
Original Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446396/
https://ncbi.nlm.nih.gov/pubmed/32914017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00297
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires